During the 2024 AAPS PHarmSCi 360 conference in Salt Lake City, Dr. Yow-Ming Wang, associate director for biosimilars and therapeutic biologics in the Immediate Office of Clinical Pharmacology at CDER ...

CellCarta and Imagene AI today announced an expanded collaboration to provide a coordinated path for biopharma companies to validate, deploy, and scale AI-powered biomarker and companion diagnostic ...

In this free webinar, learn how biomarker strategies can support earlier disease detection and more efficient neurodegeneration trials. The featured speakers will discuss biological, imaging, digital ...

‘Precision’ means comprehending disease biology, targeting pathways, and, most importantly, choosing appropriate patients. This precision-driven strategy relies ...

Different genomic alterations in DNA damage repair (DDR) pathways occur in 20% to 25% of advanced prostate cancer, including homologous recombination repair (HRR) gene alterations. Identifying the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...

Earnings Call Insights: ALX Oncology Holdings Inc. (ALXO) Q3 2025 The company reiterated that the ASPEN-Breast Phase II trial is "on track to dose its first patient this quarter," with interim data ...

Early cancer detection remains one of the most important challenges in oncology, with major implications for patient outcomes, treatment selection, and ...

Despite modern imaging and genetic testing, diagnosing amyotrophic lateral sclerosis (ALS) remains challenging, particularly when distinguishing it from clinically similar neurodegenerative disorders.

Despite their importance, a significant number of biomarker strategies fail because they are added too late, are not feasible in real clinical settings, or are poorly aligned with clinical endpoints.

Explore evolving options for biomarker-negative metastatic breast cancer, from CDK4/6 rechallenge to gadeptolizumab and PAM-pathway targeted therapy. The discussion focuses on treatment selection for ...